ReviewJournal of biomedicine & biotechnology2012
SPECT molecular imaging in Parkinson's disease.
Review in Journal of biomedicine & biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Imaging analysis of Parkinson's disease patients using SPECT and tractography.Scientific reports · 2016Trial
- Parkinson's Disease: From Bench to Bedside-Advancements in Diagnosis and Therapeutics using Pharmacogenomic Approach.Current gene therapy · 2026Review
- Development of Positron Emission Tomography Radiotracers for Imaging α-Synuclein Aggregates.Cells · 2025Review
- Decreased homovanillic acid and 5-hydroxyindoleacetic acid levels in the cerebrospinal fluid of patients with Dravet syndrome with parkinsonism.Epilepsia open · 2025Article
- AI in SPECT Imaging: Opportunities and Challenges.Seminars in nuclear medicine · 2025Review
- Article
- Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.Journal of Parkinson's disease · 2023Article
- Topological analysis of functional connectivity in Parkinson's disease.Frontiers in neuroscience · 2023Article
- Diagnostic and therapeutic agents that target alpha-synuclein in Parkinson's disease.Journal of neurology · 2022Review
- Evaluation of Brain SPECT withParkinson's disease · 2022Article
- Effect of white matter hyperintensity on dopamine transporter availability of striatum measured by F-18 FP-CIT PET.Japanese journal of radiology · 2021Article
- Alpha-Synuclein as a Biomarker of Parkinson's Disease: Good, but Not Good Enough.Frontiers in aging neuroscience · 2021Review
- A Novel Automatic Approach for Calculation of the Specific Binding Ratio in [I-123]FP-CIT SPECT.Diagnostics (Basel, Switzerland) · 2020Article
- Current Status of Stem Cell-Derived Therapies for Parkinson's Disease: From Cell Assessment and Imaging Modalities to Clinical Trials.Frontiers in neuroscience · 2020Review
- Feasible Classified Models for Parkinson Disease fromSensors (Basel, Switzerland) · 2019Article
- Comparative Study of Two Oxidizing Agents, Chloramine T and Iodo-GenPharmaceuticals (Basel, Switzerland) · 2019Article
- Dopamine Transporter maging with Tc-99m TRODAT-1 SPECT in Parkinson's isease and its orrelation with linical isease everity.Asia Oceania journal of nuclear medicine & biology · 2019Article
- miR-185 and SEPT5 Genes May Contribute to Parkinson's Disease Pathophysiology.Oxidative medicine and cellular longevity · 2019Article
- Imaging of Motor Cortex Physiology in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2018Review
- Degree of dopaminergic degeneration measured byNeural regeneration research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a common disorder, and the diagnosis of Parkinson's disease is clinical and relies on the presence of characteristic motor symptoms. The accuracy of the clinical diagnosis of PD is still limited. Functional neuroimaging using SPECT technique is helpful in patients with first signs of parkinsonism. The changes detected may reflect the disease process itself and/or compensatory responses to the disease, or they may arise in association with disease- and/or treatment-related complications. This paper addresses the value of SPECT in early differential diagnosis of PD and its potential as a sensitive tool to assess the pathophysiology and progression, as well as the therapeutic efficacy of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.